Among NSCLC, a lower CTL level indicates better patient survival, but only when IL-17A has a high expression level (p < 0.05), or IL-17C or IL-25 has a low expression level (p < 0.05). This evidence concerns the gene IL17C and non-small cell lung carcinoma.